비용종 동반 만성 부비동염 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• According to DelveInsight's estimates, the total CRSwNP diagnosed prevalent cases in the 7MM, were ~4,404 thousand in 2023.
• In 2023, the market size of CRSwNP was highest in the US among the 7MM, accounting for approximately USD 1,674 million which is further expected to increase by 2036.
• The current Chronic Rhinosinusitis with Nasal Polyps Treatment includes Corticosteroids (first line and second line), DUPIXENT, NUCALA, XOLAIR, and others, an approved drug for the treatment of Chronic Rhinosinusitis with Nasal Polyps.
• The different pharmacological therapies used to treat CRSwNP belong mainly to classes of first-line treatment and refractory treatment, used for the management of the disease.
• The emerging drug FASENRA is expected to launch in the US by 2025, in EU4 and the UK by 2026, and in Japan by 2027, which has the potential to reduce the disease burden of Chronic Rhinosinusitis with Nasal Polyps in the forecasted years.

Request for Sample Page of the "Chronic Rhinosinusitis with Nasal Polyps Drugs Market"

DelveInsight's "Chronic Rhinosinusitis with Nasal Polyps Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of CRSwNP, historical and forecasted epidemiology as well as the Chronic Rhinosinusitis with Nasal Polyps market trends in the United States, EU4, and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The CRSwNP Drugs Market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Chronic Rhinosinusitis with Nasal Polyps market size from 2022 to 2036. The Report also covers current Chronic Rhinosinusitis with Nasal Polyps Treatment Market practices, Chronic Rhinosinusitis with Nasal Polyps Market Drivers, market barriers, SWOT analysis, reimbursement and market access, and Chronic Rhinosinusitis with Nasal Polyps unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

Key Factors Driving the Growth of the Chronic Rhinosinusitis with Nasal Polyps Market

• Rising CRSwNP Disease Burden: CRSwNP is expected to see a rising disease burden over the forecast period (2026-2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches.
• Impact of Nucala and Xolair Approvals on CRSwNP Treatment: The coveted approvals of NUCALA and XOLAIR in the overall existing treatment have added effectiveness in treating CRSwNP.
• Launch of Emerging CRSwNP Therapies: The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others.

Chronic Rhinosinusitis with Nasal Polyps Treatment Market

Nasal Polyposis/Nasal polyps is small, benign drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyps are a subgroup of chronic rhinosinusitis. Chronic rhinosinusitis is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from chronic rhinosinusitis condition can be progressed into Chronic Rhinosinusitis with Nasal Polyps, and chronic rhinosinusitis without NP (CRSsNP). Only a portion of chronic rhinosinusitis will develop nasal polyps.

CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, and cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are more prone to get nasal polyps. Patients suffering from nasal polyps may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.

Chronic Rhinosinusitis with Nasal Polyps Diagnosis

For the diagnosis of nasal polyps, an ENT specialist or any other physician first looks into the nasal passages with a special lighted instrument known as a nasoscope. The most preferred techniques are confirming the location, size, and severity of polyps nasal endoscopy, and radiological imaging. Further allergy tests and blood tests can be done to determine other disease-related components.

Chronic Rhinosinusitis with Nasal Polyps Treatment

Corticosteroids are considered the first-line therapy for the treatment of nasal polyps. Initially, nasal corticosteroids are recommended for treatment. If the patient does not progress, they may be shifted to oral corticosteroids and then to injectable corticosteroids. If the corticosteroids do not show progress in the condition, surgical intervention is the next treatment of choice. Biologics can be given to treat severe polyps, treat post-surgery reoccurrence cases, and treat patients who cannot undergo surgery. Anti-allergic NSAIDs can be added to the regimen depending on the condition.

The currently recommended range of pharmacological treatments includes mainly biologics and corticosteroids, including NUCALA (mepolizumab), DUPIXENT (dupilumab), XOLAIR (omalizumab), XHANCE (fluticasone propionate), SINUVA (mometasone furoate) Sinus Implant, and PROPEL (mometasone furoate) as currently approved for treating nasal polyps and CRSwNP. With many treatment options already present, the market anticipates the launch of emerging products with novel CRSwNP MoA targets and the onset of action.

CRSwNP is a complex and frequent respiratory condition that poses significant challenges to both the patients who experience it and the physicians who treat them. Treatment aims to eliminate or significantly reduce the size of the nasal polyps, resulting in relief of nasal obstruction, improvement in sinus drainage, and restoration of olfaction and taste. A handful of clinical trials are expected to change the landscape of the emerging therapeutic market in the forecast period. Profound disease understanding, development of novel therapeutic agents, and patient-centered treatment approaches will improve patient outcomes in the coming years.

Chronic Rhinosinusitis with Nasal Polyps Epidemiology

As the market is derived using a patient-based model, the CRSwNP epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent cases of Chronic Rhinosinusitis (CRS), Diagnosed prevalent cases of CRS, Diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps, and Gender-specific diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps, in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2022 to 2036.

• The total prevalent cases of CRS in the 7MM were found to be approximately 71 million cases in 2025, which are expected to increase at a significant CAGR during the study period (2022-2036).
• Based on DelveInsight's estimations, total diagnosed prevalent cases of CRS in the 7MM were found to be nearly 18 million in 2025, which are expected to increase at a significant CAGR during the forecast period of 2026-2036.
• As per DelveInsight's estimates, the 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period. As per DelveInsight's analysis, in the United States 25% of the total diagnosed prevalent cases of CRS develop into CRSwNP.
• As per DelveInsight's epidemiology model for CRSwNP, the US had the highest diagnosed prevalent cases of CRSwNP in the 7MM with around 2 million cases in 2025. The gender distribution of the disease suggests a male predominance in the US, with 55% of the diagnosed prevalent cases of CRSwNP being males.

Chronic Rhinosinusitis with Nasal Polyps Recent Developments

• In February 2026, GSK announced that the European Commission had authorized EXDENSUR (depemokimab) as an add-on treatment alongside intranasal corticosteroids for adults with severe CRSwNP who remain insufficiently controlled despite systemic corticosteroids and/or surgery.
• In January 2026, GSK reported that Japan's Ministry of Health, Labour and Welfare approved EXDENSUR (depemokimab) for the treatment of CRSwNP in patients inadequately controlled with standard therapy.
• In December 2025, the US FDA approved depemokimab for severe asthma but did not approve the CRSwNP indication, without providing detailed reasons. GSK has expressed continued confidence in the therapy's potential for CRSwNP and is maintaining discussions with the FDA.
• In October 2025, TEZSPIRE was approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled CRSwNP, making it the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.
• In September 2025, Upstream Bio reported positive top-line results from the Phase II VIBRANT trial evaluating verekitug for the treatment of CRSwNP. In the 24-week study, verekitug administered at 100 mg every 12 weeks met its primary endpoint, demonstrating a statistically significant and clinically meaningful placebo-adjusted reduction in endoscopic nasal polyp score (NPS) of -1.8.

Chronic Rhinosinusitis with Nasal Polyps Drug Chapters

The drug chapter segment of the CRSwNP Drugs Market Report encloses a detailed analysis of Chronic Rhinosinusitis with Nasal Polyps off-label drugs and late-stage (Phase-III and Phase-II) Chronic Rhinosinusitis with Nasal Polyps pipeline drugs. It also helps to understand the Chronic Rhinosinusitis with Nasal Polyps clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic Rhinosinusitis with Nasal Polyps Marketed Drugs

• NUCALA (mepolizumab): GlaxoSmithKline

GSK's NUCALA (mepolizumab) is the first IL-5 therapy approved as an add-on treatment in the US for adults with CRSwNP to target eosinophilic inflammation in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. The recommended dosage of mepolizumab is 100 mg, administered once every 4 weeks by subcutaneous injection into the upper arm, thigh, or abdomen.

Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. By inhibiting IL-5 signaling, mepolizumab reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.

The US FDA approved NUCALA in July 2021 based on positive results from the pivotal SYNAPSE study.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs

• Verekitug (UPB-101): Upstream Bio

Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation.

• Depemokimab (GSK3511294): GSK

GSK is developing depemokimab for the treatment of CRSwNP. It is a humanized anti-interleukin-5 (IL-5) monoclonal antibody designed as a novel biologic with high binding affinity and sustained suppression of IL-5-mediated activity, enabling prolonged control of eosinophilic inflammation.

Chronic Rhinosinusitis with Nasal Polyps Market Outlook

The Chronic Rhinosinusitis with Nasal Polyps Market Outlook is anticipated to evolve largely due to the quick approvals of new therapies by regulatory agencies like the European Commission and the US FDA. The current market for CRSwNP is undergoing a boom with the approval of biologics that target uncontrolled severe nasal polyps cases and can be given post-surgery in the recurrence of Nasal polyp cases.

Various FDA-approved therapies by major key pharmaceutical players are available in the Chronic Rhinosinusitis with Nasal Polyps Drugs Market, including branded biologics that include NUCALA (mepolizumab), DUPIXENT (dupilumab), and XOLAIR (omalizumab), along with other treatment options like XHANCE (fluticasone propionate), SINUVA (mometasone furoate) Sinus Implant, and PROPEL (mometasone furoate). Among the 7MM, the major share of the market was captured by Corticosteroids.

With a handful number of clinical trials in the CRSwNP emerging pipeline, TEZSPIRE is under development by AstraZeneca and Amgen for treating CRSwNP and is currently in Phase III of development for CRSwNP treatment along with other emerging options. Considering the treatment paradigm for CRSwNP, a substantial market has been designated toward biologics where many potential candidates like DUPIXENT and others have marked their coveted entries; the market looks forward to catering to other biologics under development.

In the upcoming Chronic Rhinosinusitis with Nasal Polyps treatment market landscape, there are a plethora of companies investigating agents for use in Chronic Rhinosinusitis with Nasal Polyps which includes AstraZeneca, Amgen and others. There are many more pharma companies which are conducting clinical trials for therapies for Chronic Rhinosinusitis with Nasal Polyps.

• The Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Size in the 7MM was approximately USD 2,249 million in 2023, the market is expected to grow during the forecast period (2026-2036) attributed to the biologic therapies, and others.
• The United States accounted for the highest Chronic Rhinosinusitis with Nasal Polyps Market Size approximately 74% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• Among the European countries, Germany had the highest Chronic Rhinosinusitis with Nasal Polyps market size with nearly USD 161 million in 2023, while Spain had the lowest market size of Chronic Rhinosinusitis with Nasal Polyps with nearly USD 44 million in 2023.
• The Chronic Rhinosinusitis with Nasal Polyps Market Size in Japan was estimated to be nearly USD 88 million in 2023, which accounts for 4% of the total 7MM market.
• With the expected launch of upcoming therapies, such as TEZSPIRE (tezepelumab) the total market size of Chronic Rhinosinusitis with Nasal Polyps is expected to show change in the upcoming years.

Chronic Rhinosinusitis with Nasal Polyps Drugs Uptake

This section focuses on the uptake rate of potential Chronic Rhinosinusitis with Nasal Polyps drugs expected to launch in the market during 2022-2036. For example, TEZSPIRE (tezepelumab) in the US is expected to be launched by 2025 with a peak share of 3.2%. TEZSPIRE is anticipated to take 7 years to peak with a medium uptake.

Chronic Rhinosinusitis with Nasal Polyps Pipeline Development Activities

The Chronic Rhinosinusitis with Nasal Polyps pipeline report provides insights into different Chronic Rhinosinusitis with Nasal Polyps clinical trials within Phase III, Phase II, and Phase I. It also analyzes key Chronic Rhinosinusitis with Nasal Polyps Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Chronic Rhinosinusitis with Nasal Polyps clinical trials report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Chronic Rhinosinusitis with Nasal Polyps emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Chronic Rhinosinusitis with Nasal Polyps evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Wright State University Boonshoft School of Medicine, Fairborn, US; University of California San Diego, San Diego, California, US; Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, US; University of Siena, Italy; University of Southampton, Southampton, UK; University of Fukui, Fukui, Japan; Nippon Medical School, Tokyo, Japan; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Chronic Rhinosinusitis with Nasal Polyps Therapeutis Market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Chronic Rhinosinusitis with Nasal Polyps Drugs Market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Chronic Rhinosinusitis with Nasal Polyps Drugs Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The Chronic Rhinosinusitis with Nasal Polyps Drugs Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Report Scope

• The CRSwNP Therapeutics Market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the Chronic Rhinosinusitis with Nasal Polyps epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market, historical and forecasted Chronic Rhinosinusitis with Nasal Polyps market size, Chronic Rhinosinusitis with Nasal Polyps market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Chronic Rhinosinusitis with Nasal Polyps Drugs Market.

Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Report Insights

• Patient-based CRSwNP Market Forecsting
• CRSwNP Therapeutic Approaches
• CRSwNP Pipeline Analysis
• CRSwNP Market Size
• CRSwNP Market Trends
• Existing and Future CRSwNP Therapeutics Market Opportunities

Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Report Key Strengths

• 11 years Chronic Rhinosinusitis with Nasal Polyps Market Forecast
• The 7MM Coverage
• CRSwNP Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• CRSwNP Drugs Uptake
• Key CRSwNP Market Forecast Assumptions

Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market Report Assessment

• Current CRSwNP Treatment Market Practices
• CRSwNP Unmet Needs
• CRSwNP Pipeline Product Profiles
• CRSwNP Treatment Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• CRSwNP Market Barriers
• CRSwNP Market Barriers

Key Questions Answered In The CRSwNP Market Report:

CRSwNP Treatment Market Insights

• What was the CRSwNP market share (%) distribution in 2022 and what it would look like in 2036?
• What would be the Chronic Rhinosinusitis with Nasal Polyps market size as well as market size by therapies across the 7MM during the forecast period (2026-2036)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Chronic Rhinosinusitis with Nasal Polyps market size during the forecast period (2026-2036)?
• At what CAGR, the Chronic Rhinosinusitis with Nasal Polyps Treatment Market is expected to grow at the 7MM level during the forecast period (2026-2036)?
• What would be the Chronic Rhinosinusitis with Nasal Polyps Market Outlook across the 7MM during the forecast period (2026-2036)?
• What would be the Chronic Rhinosinusitis with Nasal Polyps Market growth till 2036 and what will be the resultant market size in the year 2036?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

CRSwNP Epidemiology Insights

• What are the disease risk, burden, and Chronic Rhinosinusitis with Nasal Polyps Unmet Needs?
• What is the historical Chronic Rhinosinusitis with Nasal Polyps patient population in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient population of Chronic Rhinosinusitis with Nasal Polyps at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Rhinosinusitis with Nasal Polyps?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Rhinosinusitis with Nasal Polyps during the forecast period (2026-2036)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2026-2036)?

Current CRSwNP Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of CRSwNP along with the approved therapy?
• What are the current treatment guidelines for the treatment of Chronic Rhinosinusitis with Nasal Polyps in the US, Europe, And Japan?
• What are the CRSwNP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many CRSwNP companies are developing therapies for the treatment of Chronic Rhinosinusitis with Nasal Polyps?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Chronic Rhinosinusitis with Nasal Polyps?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the CRSwNP therapies?
• What are the recent therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for CRSwNP and their status?
• What are the key designations that have been granted for the Chronic Rhinosinusitis with Nasal Polyps Emerging Therapies?
• What are the 7MM historical and forecasted CRSwNP Treatment Market?

Reasons to Buy CRSwNP Market Forecast Report

• The Chronic Rhinosinusitis with Nasal Polyps Drugs Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Rhinosinusitis with Nasal Polyps Treatment Market.
• Insights on patient burden/disease Chronic Rhinosinusitis with Nasal Polyps Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the Chronic Rhinosinusitis with Nasal Polyps Drugs Market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Chronic Rhinosinusitis with Nasal Polyps Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. CRSwNP Market Overview at a Glance

• 3.1. Market Share (%) Distribution of CRSwNP by Therapies in 2022
• 3.2. Market Share (%) Distribution of CRSwNP by Therapies in 2036

4. Epidemiology And Market Forecast Methodology

5. Executive Summary of CRSwNP

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction to CRSwNP
• 7.2. Signs and Symptoms
• 7.3. Etiology
• 7.4. Causes
• 7.5. Pathogenesis
• 7.6. Diagnostic Approach
  • 7.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
  • 7.6.2. Diagnostic Algorithm
• 7.7. Treatment and Management
  • 7.7.1. Treatment Algorithm
  • 7.7.2. Treatment Recommendations
    • 7.7.2.1. International Consensus Statement on Rhinology and Allergy
    • 7.7.2.2. European forum for research and education in allergy and airway diseases

8. CRSwNP Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Methodology of Epidemiology
• 8.3. Assumptions and Rationale: the 7MM
  • 8.3.1. The US
  • 8.3.2. The EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • 8.3.3. Japan
• 8.4. Total Diagnosed Prevalent Cases of CRS in the 7MM
  • 8.4.1. Total Diagnosed Prevalent Cases of CSRwNP in the 7MM
• 8.5. The United States
  • 8.5.1. Prevalent Cases of CRS in the US
  • 8.5.2. Diagnosed Prevalent Cases of CRS in the US
  • 8.5.3. Diagnosed Prevalent Cases of CRSwNP in the US
  • 8.5.4. Gender-specific Diagnosed Prevalent Cases of CRSwNP in the US
• 8.6. EU4 and the UK
  • 8.6.1. Prevalent Cases of CRS in the EU4 and the UK
  • 8.6.2. Diagnosed Prevalent Cases of CRS in the EU4 and the UK
  • 8.6.3. Diagnosed Prevalent Cases of CRSwNP in the EU4 and the UK
  • 8.6.4. Gender-specific Diagnosed Prevalent Cases of CRSwNP in the EU4 and the UK
• 8.7. Japan
  • 8.7.1. Prevalent Cases of CRS in Japan
  • 8.7.2. Diagnosed Prevalent Cases of CRS in Japan
  • 8.7.3. Diagnosed Prevalent Cases of CRSwNP in Japan
  • 8.7.4. Gender-specific Diagnosed Prevalent Cases of CRSwNP in Japan

9. CRSwNP Patient Journey

10. CRSwNP Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. NUCALA (mepolizumab): GlaxoSmithKline
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. XHANCE (fluticasone propionate): Optinose US Inc.
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental activities
  • 10.3.4. Clinical Development
  • 10.3.5. Clinical Trials Information
  • 10.3.6. Safety and Efficacy
  • 10.3.7. Product Profile
• 10.4. DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. XOLAIR (omalizumab): Hoffmann-La Roche/Novartis
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile
• 10.6. SINUVA (mometasone furoate) Sinus Implant: Intersect ENT
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Clinical Development
  • 10.6.4. Clinical Trials Information
  • 10.6.5. Safety and Efficacy
  • 10.6.6. Product Profile
• 10.7. PROPEL (mometasone furoate): Intersect ENT
  • 10.7.1. Product Description
  • 10.7.2. Regulatory Milestones
  • 10.7.3. Other Developmental activities
  • 10.7.4. Clinical Development
  • 10.7.5. Clinical Trials Information
  • 10.7.6. Safety and Efficacy
  • 10.7.7. Product Profile

11. Emerging CRSwNP Drugs

• 11.1. Key Cross Competition
• 11.2. FASENRA (benralizumab): AstraZeneca
  • 11.2.1. Product Description
  • 11.2.2. Development activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. TEZSPIRE (tezepelumab): AstraZeneca/Amgen
  • 11.3.1. Product Description
  • 11.3.2. Development activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. Depemokimab/GSK3511294: GlaxoSmithKline
  • 11.4.1. Product Description
  • 11.4.2. Clinical Development
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Product Profile
  • 11.4.5. Analysts' Views
• 11.5. CM310: Keymed Biosciences
  • 11.5.1. Product Description
  • 11.5.2. Clinical Development
  • 11.5.3. Clinical Trials Information
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Product Profile
  • 11.5.6. Analysts' Views
• 11.6. NURTEC (rimegepant): Biohaven Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Clinical Development
  • 11.6.3. Clinical Trials Information
  • 11.6.4. Product Profile
  • 11.6.5. Analysts' Views

12. CRSwNP: Market Analysis

• 12.1. Key Findings
• 12.2. Methodology of CRSwNP Market
• 12.3. Key Market Forecast Assumptions
• 12.4. Market Outlook
• 12.5. Attribute Analysis
• 12.6. Market Size of CRSwNP in the 7MM
• 12.7. Market Size of CRSwNP by Therapies in the 7MM
• 12.8. Market Size of CRSwNP in the US
  • 12.8.1. Total Market Size of CRSwNP
  • 12.8.2. Market Size of CRSwNP by Therapies
• 12.9. Market Size of CRSwNP in the EU4 and the UK
  • 12.9.1. Total Market Size of CRSwNP
  • 12.9.2. Market Size of CRSwNP by Therapies
• 12.10. Market Size of CRSwNP in Japan
  • 12.10.1. Total Market Size of CRSwNP
  • 12.10.2. Market Size of CRSwNP by Therapies

13. KOL Views

• 13.1. The United States
• 13.2. The EU4 and the UK
• 13.3. Japan

14. SWOT Analysis

15. CRSwNP Unmet Needs

16. Reimbursement and Market Access

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight